Addition Technology Receives Canadian Approval for Intacs® and Intacs® SK

Oct. 26, 2008 - PRLog -- Des Plaines, IL, February 20, 2008 – Addition Technology, Inc., the maker of Intacs corneal implants for the treatment of keratoconus and myopia, announced today that it has received regulatory clearance from Health Canada to market Intacs corneal implants for keratoconus and myopia indications.

“I have used Intacs in my practice for two years and feel that Intacs is an excellent option in treating many keratoconic patients,” said David Rootman, M.D., Toronto, Canada. “Many of my patients who are young have difficulty seeing due to the onset of the disease and until now had to live with poor functional vision or have gone on to corneal transplant surgery.  With the addition of Intacs, I can offer them much improved vision through a minimally invasive procedure and avoid a transplant.”  

Patients failing to achieve a successful contact lens fit have historically been faced with a corneal transplant with a 12 to 18 month recovery period. Intacs and Intacs SK are far less risky options to provide keratoconus patients with functional vision.  

“Over the past couple of years there has been considerable interest in Intacs in Canada.  We have trained quite a few surgeons to date and expect this procedure to be adopted fairly rapidly within the ophthalmic community,” said William M. Flynn, president and chief executive officer of Addition Technology.  

“I-MED is excited about carrying the Intacs line in Canada and in anticipation have trained our staff on the product and will be in position to offer the highest level of customer service, which is a trademark of the way we do business,” said Ilan Hofmann, president and chief executive officer, I-MED Pharma Inc. “We are also looking forward to introducing AlphaCor, Addition Technology’s artificial cornea and AlphaSphere, it orbital implant currently in development, over the next 12 months,” he added.   

Addition Technology, Inc., a privately held company, specializes in novel solutions for sight-threatening eye indications. Intacs® corneal implants and the AlphaCor™ artificial cornea are patented devices, and the first of their kind, cleared by the FDA and granted CE Mark certification in Europe in addressing vision threatening conditions of the cornea. Intacs corneal implants are indicated for keratoconus and myopia. AlphaCor artificial cornea is indicated as an alternative for high-risk, repeat graft failures. Both products are distributed worldwide.  

I-MED Pharma is a leading privately held Canadian manufacturer and distributor of ophthalmic surgical and topical products with offices in Montreal, QC Canada. I-MED is the manufacturer of a number of ophthalmic products such as I-Visc(c), I-Cel(c), I-Lens(c), Acri-Lens(c), I-Drop(c), and I-Lid ‘n Lash(c) which are distributed worldwide. I-MED is also the exclusive Canadian distributor for a number of US, European and Internationally recognized manufactures including Moria, Rayner, Optonol, Oertli, Addition Technology and Ophthalmic Innovations International. Visit www.IntacsForKeratoconus.com and www.AlphaCor-ati.com for more information.

# # #

Addition Technology, Inc. is a privately held eye care company, specializing in novel solutions for sight-threatening eye indications.